Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GPCR | Structure Therapeutics Inc.

Index- P/E- EPS (ttm)-2.02 Insider Own0.10% Shs Outstand38.25M Perf Week4.72%
Market Cap1.26B Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float36.22M Perf Month13.97%
Income-65.50M PEG- EPS next Q-0.22 Inst Own41.29% Short Float / Ratio6.66% / 5.16 Perf Quarter16.61%
Sales- P/S- EPS this Y-20.70% Inst Trans- Short Interest2.41M Perf Half Y48.98%
Book/sh5.61 P/B6.09 EPS next Y-7.80% ROA- Target Price48.80 Perf Year-
Cash/sh6.10 P/C5.60 EPS next 5Y- ROE- 52W Range20.80 - 42.55 Perf YTD31.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-19.65% Beta-
Dividend %- Quick Ratio15.20 Sales past 5Y- Gross Margin- 52W Low64.37% ATR1.94
Employees77 Current Ratio15.20 Sales Q/Q- Oper. Margin- RSI (14)60.64 Volatility6.29% 6.06%
OptionableNo Debt/Eq0.00 EPS Q/Q-44.00% Profit Margin- Rel Volume1.34 Prev Close34.15
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume467.46K Price34.19
Recom1.40 SMA2011.92% SMA509.97% SMA20021.27% Volume476,647 Change0.12%
Date Action Analyst Rating Change Price Target Change
Jul-27-23Initiated Piper Sandler Overweight $58
May-25-23Resumed Jefferies Buy $34 → $41
Feb-28-23Initiated SVB Securities Outperform $33
Feb-28-23Initiated Jefferies Buy $34
Feb-28-23Initiated Guggenheim Buy $50
Feb-28-23Initiated BMO Capital Markets Outperform $40
Aug-10-23 04:05PM
Aug-03-23 05:32PM
Jul-16-23 07:00AM
Jun-27-23 02:10PM
08:12AM Loading…
Jun-26-23 09:05PM
Jun-16-23 08:00AM
Jun-13-23 06:10AM
Jun-12-23 10:15AM
Jun-07-23 08:30AM
May-31-23 04:30PM
May-25-23 04:30PM
May-18-23 04:30PM
May-11-23 04:30PM
06:59AM Loading…
May-03-23 06:59AM
Mar-30-23 04:30PM
Feb-07-23 04:00PM
Feb-06-23 03:17PM
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.